4月29日 - ** 制药商Abeona Therapeutics ABEO.O股价盘前上涨12.7%，报6.03美元
** ABEO称 (link)，美国FDA已经批准了其治疗一种罕见皮肤病的基因疗法。
** 这种名为Zevaskyn的基因疗法被批准用于治疗成人和儿童隐性萎缩性表皮松解症患者。
** 目前的标准治疗方法是日常伤口护理和保护性包扎
** 公司称该疗法预计将于 2025 年第三季度上市
** 截至上一交易日收盘，ABEO股价累计下跌4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.